ArticleBioMed research international2026
Celastrol Enhanced Doxorubicin-Mediated Apoptosis in Saos-2 Osteosarcoma Cells.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis.Scientific reports · 2026Article
- Celastrol Enhanced Doxorubicin-Mediated Apoptosis in Saos-2 Osteosarcoma Cells.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteosarcoma is one of the most lethal types of human malignancy in the world. Natural compounds found in certain plant foods are considered chemotherapeutic agents that exert their effects through antiproliferative, proapoptotic, and pro-oxidant properties associated with cancer.
objectiveIn this study, we investigated the effects of celastrol on the doxorubicin-mediated apoptosis in osteosarcoma cells. Saso-2 cancer cells were treated with ascending concentrations of doxorubicin and celastrol alone or in combination.
methodsCytotoxicity was measured using the MTT assay. Flow cytometry with Annexin V-FITC/PI double staining was performed to quantify apoptotic cell populations. Western blot and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) were used to measure the protein and mRNA expression levels of apoptosis mediators. An ELISA kit measured apoptosis.
resultIn Saos-2 cells, celastrol enhanced the cytotoxic effects of doxorubicin. A combination of doxorubicin and celastrol had a more potent effect on apoptosis induction and modulation of mRNA and protein levels of key apoptotic mediators, including Bax, Bcl-2, caspase-3, cytochrome c, and p53.
conclusionOverall, this study revealed that doxorubicin and celastrol could significantly potentiate doxorubicin-mediated apoptosis in osteosarcoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.